Optimize Surveillance with Sensitive, Standardized Analytical Assays, Clinically Validated MRD Tests & Reliable ctDNA Surrogate Biomarkers to Detect Disease Earlier & Improve Patient Outcomes
November 7-9, 2023 | Boston, MA
Welcome to the 2nd Liquid Biopsy Surveillance & Early Detection Summit
Accelerating Patient Access to Early & Affordable Detection & Surveillance Tests
The 2nd Liquid Biopsy Surveillance & Early Detection Summit returns as industry’s only meeting showcasing biopharma-led case studies and assay developer technical progress to create a commercially viable path forward for non-invasive testing to support early disease pipeline progress.
Ensure your whole team stays connected and ahead of the curve with unmatched industry insights across key challenges in scaling sensitive assays that enable earlier detection and utilizing ctDNA as a surrogate biomarker to improve surveillance for a paradigm shift towards achieving personalized treatment options.
Uniting patients, diagnostics and drug developers, this meeting is your one and only opportunity to learn about the latest advancements in liquid biopsy detection and early surveillance in oncology, neurology and rare disease, and how they can be implemented into clinical trials and in healthy populations.
2022 Speaker Faculty Included
Precision Medicine Global Director
VP, Global Head Precision Dx
Our 2023 Partners
Hear What Experts 2022 Attendees Had to Say…
“The event offered a great opportunity to network and promote my company and its services to advance the study in cancer treatment”
Translational Medicine Scientist, Burning Rock Biotech
“I really enjoyed the fact that we had the first LBx-focused summit here in the Boston area. I enjoyed networking with my fellow ex-colleagues, partners and collaborators”
LBx Strategy Lead, Precision Medicine & CDx, Takeda
“I enjoyed discussing the emerging clinical data and pathways towards clinical implantation for patient benefit”
WW Medical Lead, Bristol Myers Squibb